Exhibit 99.1

PRESS RELEASE

ALLERGAN AND ENTREMED ANNOUNCE STRATEGIC ALLIANCE FOR EYE DISEASES

Allergan to Develop EntreMed's Panzem(TM) for Treatment of Ophthalmic
Indications...Deal Valued at $40 Million Plus

IRVINE, Calif. and ROCKVILLE, Md., Jan. 23 /PRNewswire-FirstCall/ -- Allergan
(NYSE: AGN), a global leader in ophthalmic research and development and
pharmaceutical products, and EntreMed, Inc. (Nasdaq: ENMD), a biopharmaceutical
leader in angiogenic research and product development, today announced that they
have entered into a five-year strategic alliance to develop and commercialize
small molecule angiogenic inhibitors for treatment and prevention of diseases
and conditions of the eye.

Angiogenic inhibitors block the formation of blood vessels associated with over
80 different diseases. EntreMed's Panzem(TM) (2-methoxyestradiol (2ME2)) is the
first small molecule to be licensed, developed and marketed under this
agreement. If Allergan chooses to develop any of EntreMed's other small
molecules, the terms of the agreement will apply to each clinical candidate.
Allergan and EntreMed will co-develop Panzem(TM) to treat age-related macular
degeneration (ARMD), a leading cause of blindness that is the result of bleeding
from ruptured new blood vessels that form under the retina. A key part of this
alliance will be the assessment of Oculex Pharmaceuticals' novel drug delivery
technology to provide localized administration of Panzem(TM) to the back of the
eye.

Under the terms of the agreement, Allergan will receive an exclusive worldwide
license to commercialize Panzem(TM) for ophthalmologic uses. In return, EntreMed
will receive up to $41 million in the form of initial cash payments, equity
investments and milestone payments. EntreMed will also receive development
funding, as well as royalties on worldwide sales of future products resulting
from the collaboration. Additionally, the agreement provides for potential
co-promotion by both companies. EntreMed retains all rights to Panzem(TM) for
uses outside ophthalmology.

The use of Panzem(TM) for age-related macular degeneration represents Allergan's
first external compound that will be assessed for development using Oculex
Pharmaceuticals' proprietary biodegradable drug delivery platform technology. If
successfully developed in this proprietary system, Oculex will manufacture
finished goods. Allergan and Oculex entered into a strategic alliance in May of
2001 to develop proprietary biodegradable drug delivery products for localized
delivery to the back of the eye.

"This agreement represents excellent news for the millions of people afflicted
with age-related macular degeneration," said David E.I. Pyott, Allergan's
Chairman, President and CEO. "EntreMed brings its significant scientific
expertise in angiogenesis and the drug candidate Panzem(TM) to the partnership.
Allergan brings to the partnership its global marketing capabilities, strong
position in ophthalmic pharmaceutical research and

development and, through its partnership with Oculex, a broad expertise in
polymeric formulations and micro-sized manufacturing of novel drug delivery
products for the eye."

Dr. John Holaday, Chairman and Chief Executive Officer of EntreMed, commented,
"By partnering with Allergan, a world leader in eye therapy, we will now have
the opportunity to pursue broader commercial applications for our proprietary
drug candidate Panzem(TM). This partnership for the development of Panzem(TM)
for ophthalmic indications builds on our extensive preclinical and clinical
development program and our leadership in angiogenic inhibitor drug development.
We remain committed to and on track with the development of angiogenic
inhibitors, including Panzem(TM), for oncology. However, strategic partnerships,
such as this one with Allergan, allow us to accelerate the clinical and
commercial development of our drug candidates in a variety of angiogenic
diseases beyond oncology."

"We are pleased to be part of this collaboration," commented Donald J. Eaton,
Chairman and Chief Executive Officer of Oculex Pharmaceuticals, "because it
demonstrates how the Oculex technology can facilitate important advancements in
new drug development for the treatment of serious eye diseases."

ABOUT AGE-RELATED MACULAR DEGENERATION

Age-related macular degeneration is the most common cause of legal blindness
among people over 50 years of age in the Western world, with one in three over
the age of 65 afflicted. Each year, approximately 10% of the estimated 13
million people with macular degeneration will suffer severe central vision loss
due to the wet or advanced form, which is characterized by bleeding from
ruptured new blood vessels that form under the central part of the retina,
called the macula. Central vision is lost from the resulting scar tissue. Each
year 200,000 individuals will lose all central vision in one or both eyes.
Currently, there is only one FDA approved treatment and no cure for ARMD.

ABOUT ANGIOGENESIS

Angiogenesis is the formation of blood vessel networks that feed disease, much
like a root system nourishes a plant. Approximately 80 diseases have angiogenic
pathology, including cancer, blindness and atherosclerosis. EntreMed's
angiogenic inhibitors work to block the growth of unwanted blood vessels that
contribute to disease progression. EntreMed targets the angiogenic process at
its most vulnerable stage, specifically endothelial cell proliferation and
migration. The company's portfolio includes Endostatin protein, Angiostatin
protein, Panzem(TM) and a pipeline of preclinical drug candidates.

ABOUT PANZEM(TM)

A naturally occurring angiogenic inhibitor, Panzem's(TM) (2- methoxyestradiol
(2ME2)) versatile properties allow a wide range of potential formulations for
drug delivery. Recent reports from the National Eye Institute with whom EntreMed
has an active Cooperative Research and Development Agreement (CRADA), have
demonstrated that ocular implants of Panzem(TM) may inhibit neovascularization
in preclinical models of age-

related macular degeneration. Panzem(TM) is currently in clinical Phase I and
Phase II trials for breast cancer, prostate cancer and multiple myeloma, a blood
cancer.

ABOUT ALLERGAN, INC.

Allergan, Inc., headquartered in Irvine, California, is a technology- driven
global health care company providing eye care and specialty pharmaceutical
products worldwide. Allergan develops and commercializes products in the eye
care pharmaceutical, ophthalmic surgical device, over-the- counter contact lens
care, movement disorder, and dermatological markets that deliver value to its
customers, satisfy unmet medical needs, and improve patients' lives. For further
information, please visit the Allergan web site at http://www.allergan.com.

ABOUT ENTREMED, INC.

EntreMed, Inc., The Angiogenesis Company(TM), is an innovative clinical- stage
biopharmaceutical company emphasizing angiogenic therapeutics that inhibit
abnormal blood vessel growth associated with a broad range of diseases such as
cancer, blindness and atherosclerosis. The company's strategy is to accelerate
development of its core technologies through collaborations and sponsored
research programs with pharmaceutical and biotechnology companies, universities
and government laboratories. EntreMed has a rich pipeline of new proteins, genes
and small molecules. For further information, visit EntreMed's web site at
http://www.entremed.com. EntreMed's majority owned subsidiary, MaxCyte, Inc.,
(http://www.maxcyte.com), develops targeted therapeutic products to treat
severe and chronic diseases.

ABOUT OCULEX

Oculex Pharmaceuticals is a leading ophthalmic drug delivery company that
develops and manufactures proprietary delivery systems to facilitate the
treatment of major sight-threatening diseases and conditions that occur inside
the eye. Oculex's proprietary drug delivery technology is the first
biodegradable, sustained-release system designed to deliver drugs directly into
the eye. This novel approach to ocular drug therapy may enable the treatment of
eye diseases, many of which were previously untreatable. For further
information, please visit the Oculex web site at http://www.oculex.com.

FORWARD LOOKING STATEMENTS

This press release contains "forward-looking statements," such as statements
regarding the potential effectiveness of Panzem(TM) and other inhibitors of
angiogenesis for the treatment of age-related macular degeneration and other eye
diseases. These statements are based on research results to date, and actual
results could vary materially from the Companies' expectations and projections.
Risks and uncertainties include the possibility that products under research and
development could be found to be scientifically, technically or clinically
impractical or unacceptable; general industry and pharmaceutical market
conditions; technological advances and patents attained by competitors;
challenges inherent in new product marketing such as the predictability of
market acceptance for new pharmaceutical products and/or acceptance of new
indications for

such products; the possibility that any therapy successfully developed may
produce varying results among patients; health care reforms; and trends toward
managed care and health care cost containment, and governmental laws and
regulations affecting domestic and foreign operations.

Additional information concerning these and other risk factors with respect to
Allergan can be found in press releases issued by Allergan as well as Allergan's
public periodic filings with the Securities and Exchange Commission, including
the discussion under the heading "Certain Factors and Trends Affecting Allergan
and Its Businesses" in Allergan's 2000 Form 10-K and Form 10-Q for the quarter
ended September 28, 2001. Copies of Allergan press releases and additional
information about Allergan are available on the World Wide Web at
http://www.allergan.com, or you can contact the Allergan Investor Relations
Department by calling 714-246-4636.

Further additional information concerning these and other risk factors with
respect to EntreMed can be found in EntreMed's public filings with the
Securities and Exchange Commission. Copies of EntreMed's public filings may be
obtained from the SEC's website at http://www.sec.gov or at EntreMed's website
at http://www.entremed.com, or you can contact the EntreMed Investor Relations
Department by calling 240-864-2640.